371 related articles for article (PubMed ID: 28434884)
1. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
3. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
6. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Vincenzi B; Frezza AM; Schiavon G; Spoto C; Silvestris N; Addeo R; Catalano V; Graziano F; Santini D; Tonini G
Support Care Cancer; 2013 May; 21(5):1313-9. PubMed ID: 23196819
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.
Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Higuera O; Burgos E; Ramos D; Calatrava A; Andrada E; López R; Moreno V; Madero R; Cejas P; Feliu J
Ann Oncol; 2014 Feb; 25(2):398-403. PubMed ID: 24351404
[TBL] [Abstract][Full Text] [Related]
8. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
[TBL] [Abstract][Full Text] [Related]
9. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Soveri LM; Lamminmäki A; Hänninen UA; Karhunen M; Bono P; Osterlund P
Acta Oncol; 2019 Apr; 58(4):398-406. PubMed ID: 30638100
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
[TBL] [Abstract][Full Text] [Related]
12. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
[TBL] [Abstract][Full Text] [Related]
13. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
15. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
[TBL] [Abstract][Full Text] [Related]
16. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Altaf R; Lund Brixen A; Kristensen B; Nielsen SE
Oncology; 2014; 87(3):167-72. PubMed ID: 25012613
[TBL] [Abstract][Full Text] [Related]
19. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
[TBL] [Abstract][Full Text] [Related]
20. FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.
de Albuquerque Ribeiro Gondinho P; de Barros Silva PG; Lisboa MRP; Costa BA; da Rocha Filho DR; Gifoni MAC; Lima MVA; Junior RCPL; Vale ML
Int J Clin Oncol; 2020 Dec; 25(12):2066-2074. PubMed ID: 32761281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]